Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Sleep, Aging and Risk for Alzheimer's Disease (SARA) Study
Authors not listed
NYU Langone Health · 2013
Abstract
Our preliminary data show for in cognitively-normal elderly, that Sleep Disordered Breathing (SDB) is associated with the increase of cerebrospinal fluid (CSF) phosphorylated-Tau (P-Tau) and total-Tau (T-Tau), decreases in medial temporal lobe glucose uptake (FDG-PET) and volume (MRI) and progressive memory decline, all of which have been shown to be useful in predicting future dementia in older adults. These findings raise the question as to whether Alzheimer's disease (AD) tissue damage causes SDB in the elderly, or alternatively, if SDB acts as a risk factor for AD neurodegeneration. In the proposed study, we will investigate these mechanistic hypotheses in cognitively normal elderly by examining the longitudinal associations between SDB and cognitive decline, novel MR neuroimaging and CSF biomarkers for neurodegeneration; while our secondary goal is to launch a pilot treatment study to aid in interpreting the mechanistic hypotheses and to examine the effects of nasal continuous positive airway pressure (CPAP) on cognitive decline and neurodegeneration.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Anonymous. (2013). Sleep, Aging and Risk for Alzheimer's Disease (SARA) Study. <em>NYU Langone Health</em>. https://clinicaltrials.gov/study/NCT01962779
Vancouver
Anonymous. Sleep, Aging and Risk for Alzheimer's Disease (SARA) Study. NYU Langone Health. 2013.
BibTeX
@misc{anon2013SleepA,
title = {Sleep, Aging and Risk for Alzheimer's Disease (SARA) Study},
author = {Anonymous},
journal = {NYU Langone Health},
year = {2013},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Wake Forest University Health Sciences 2018
Open access · US-GOV
Identifying Novel Aging Targets for Treatment of Delirium
Dementia & Neuropsychologia 2016
Open access · CC-BY
Subjective cognitive decline: The first clinical manifestation of Alzheimer's disease?
Heliyon 2024
Open access · CC-BY
Effects of chronic treatment with metformin on brain glucose hypometabolism and central insulin actions in transgenic mice with tauopathy
2022
Open access · CC0
Investigating the temporal pattern of neuroimaging-based brain age estimation as a biomarker for Alzheimer's disease related neurodegeneration
Nature Communications 2024
Open access · CC-BY
Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease
New York State Psychiatric Institute 2010
Open access · US-GOV